UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040487
Receipt number R000046212
Scientific Title Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus
Date of disclosure of the study information 2020/05/22
Last modified on 2020/11/27 17:31:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus

Acronym

Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus

Scientific Title

Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus

Scientific Title:Acronym

Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus

Region

Japan


Condition

Condition

type 1 diabetes mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify patient satisfaction in using SGLT2 inhibitors in patients with type 1 diabetes

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes of Satisfaction score measured in the DTSQ by five possible responses (varying from -2; very dissatisfied, to +2; very satisfied, varying by integers), both previous and three months subsequent to ipragliflozin administration.

Key secondary outcomes

To assess safety and efficacy, the data prior to and three months subsequent of the oral administration of the SGLT2 inhibitor were collected such as body mass index, body composition, glycated hemoglobin (HbA1c), and glycemic variability were obtained from flash glucose monitoring (FGM) systems (Free Style Libre; Abbott Diabetes Care, Witney, UK) measured for three months prior to and three months subsequent of the oral administration of the SGLT2 inhibitor. Retrospective data included the insulin dose, the number of severe hypoglycemia incidence requiring assistance, diabetic ketoacidosis, and other side effects.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

50mg of ipragliflozin

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

Type 1 diabetes mellitus obtained consent to participate in research
Patients with glycated hemoglobin (HbA1c) of 6.5% or higher and less than 10%
Patients with body mass index (BMI) of 18.5 kg/m2 or higher

Key exclusion criteria

Patients who do not agree to participate in the study
Patients judged by the attending physician that there is no indication for SGLT2 inhibitor administration

Target sample size

25


Research contact person

Name of lead principal investigator

1st name Ryoichi
Middle name
Last name Ishibashi

Organization

Kimitsu Chuo Hospital

Division name

Department of Medicine, Division of Diabetes, Endocrinology and Metabolism

Zip code

292-8535

Address

1010 Sakurai, Kisarazu-city, Chiba

TEL

+81-438-36-1071

Email

ishibashi-cib@umin.net


Public contact

Name of contact person

1st name Ryoichi
Middle name
Last name Ishibashi

Organization

Kimitsu Chuo Hospital

Division name

Department of Medicine, Division of Diabetes, Endocrinology and Metabolism

Zip code

292-8535

Address

1010 Sakurai, Kisarazu-city, Chiba

TEL

+81-438-36-1071

Homepage URL


Email

ishibashi-cib@umin.net


Sponsor or person

Institute

Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kimitsu Chuo Hospital

Address

1010 Sakurai, Kisarazu-city, Chiba

Tel

+81-438-36-1071

Email

soumu@kc-hosp.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 05 Month 22 Day


Related information

URL releasing protocol

http://link.springer.com/article/10.1007/s13300-020-00971-2

Publication of results

Partially published


Result

URL related to results and publications

http://link.springer.com/article/10.1007/s13300-020-00971-2

Number of participants that the trial has enrolled

24

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 03 Month 26 Day

Date of IRB

2019 Year 03 Month 26 Day

Anticipated trial start date

2019 Year 03 Month 26 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry

2020 Year 11 Month 12 Day

Date trial data considered complete

2020 Year 11 Month 12 Day

Date analysis concluded

2020 Year 11 Month 12 Day


Other

Other related information

http://link.springer.com/article/10.1007/s13300-020-00971-2


Management information

Registered date

2020 Year 05 Month 22 Day

Last modified on

2020 Year 11 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046212


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name